A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 681-685

  Intermesoli, Tamara ^a   Delaini, Federica ^a   Acerboni, Sara ^a   Salmoiraghi, Silvia ^a   Spinelli, Orietta ^a   Guerini, Vittoria ^a   Vannucchi, Alessandro M ^b   Mappa, Silvia ^b   Rossi, Giuseppe ^c   Rossi, Valentina ^c   Di Bona, Eros ^d   Paratore, Simona ^e   Carobbio, Alessandra ^a   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a   Bassan, Renato ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Divisione di Ematologia   (Italy)

^d Azienda Ospedaliera ULSS 6   (Spain)

^e Medical Department   (Italy)

Author keywords

FIP1L1 rearrangement; Hypereosinophilia; Imatinib; Response kinetics

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FIP1L1 GENE; GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFANT; LOW DRUG DOSE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EOSINOPHILS; FEMALE; GENE REARRANGEMENT; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70449370210     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07893.x     Document Type: Article

References (15)

1. Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., Dimitrijevic, S., Mahon, F.X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N.C. Goldman, J.M. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New England Journal of Medicine, 347, 481 487.
2. Ault, P., Cortes, J., Koller, C., Kaled, E.S. Kantarjian, H. (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Research, 26, 881 884.
3. Baccarani, M., Cilloni, D., Rondoni, M., Ottaviani, E., Messa, F., Merante, S., Tiribelli, M., Buccisano, F., Testoni, N., Gottardi, E., de Vivo, A., Giugliano, E., Iacobucci, I., Paolini, S., Soverini, S., Rosti, G., Rancati, F., Astolfi, C., Pane, F., Saglio, G. Martinelli, G. (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 92, 1173 1179.
4. Bain, B. (2004) The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica, 89, 133 137.
5. Bassan, R., Locatelli, G., Borleri, G., Salvi, A. Barbui, T. (2004) Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. Haematologica, 89, 238 239.
6. Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R. Gilliland, D.G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine, 348, 1201 1214.
7. Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., Rios, M.B., Letvak, L., Kaled, E.S. Kantarjian, H. (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101, 4714 4716.
8. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2, 561 566.
9. Gleich, G.J., Leiferman, K.M., Pardanani, A., Tefferi, A. Butterfield, J.H. (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet, 359, 1577 1578.
10. Gotlib, J. Cools, J. (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia, 22, 1999 2010.
11. Jovanovic, J.V., Score, J., Waghorn, K., Cilloni, D., Gottardi, E., Metzgeroth, G., Erben, P., Popp, H., Walz, C., Hochhaus, A., Roche-Lestienne, C., Preudhomme, C., Solomon, E., Apperley, J., Rondoni, M., Ottaviani, E., Martinelli, G., Brito-Babapulle, F., Saglio, G., Hehlmann, R., Cross, N.C., Reiter, A. Grimwade, D. (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 109, 4635 4640.
12. Klion, A.D., Bochner, B.S., Gleich, G.J., Nutman, T.B., Rothenberg, M.E., Simon, H.U., Wechsler, M.E., Weller, P.F. The Hypereosinophilic Syndromes Working Group (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. Journal of Allergy and Clinical Immunology, 117, 1292 1302.
13. Metzgeroth, G., Walz, C., Erben, P., Popp, H., Schmitt-Graeff, A., Haferlach, C., Fabarius, A., Schnittger, S., Grimwade, D., Cross, N.C., Hehlmann, R., Hochhaus, A. Reiter, A. (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. British Journal of Haematology, 143, 707 715.
14. Rothenberg, M.E. (1998) Eosinophilia. New England Journal of Medicine, 338, 1592 1600.
15. Schaller, J.L. Burkland, G.A. (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed: Medscape general medicine, 3, 9.